Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2852W HIGH $15.82
Volume
9.86 M
Value Traded
3.27 M
Short % Float
14.92%
+1.65%Week
-8.02%1 Month
-66.58%3 Month
-93.88%6 Month
-99.94%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.50 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
6.61 M
Total Shares
23.43 M
Float Shares
840.00 K
Insiders
45.58%
Institutions
2.91%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ATON Catalyst Timeline
Dated clinical, regulatory and corporate events for AlphaTON Capital Corp.
Past FDA Catalysts and PDUFA Decisions
How ATON actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ATON program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Levitt Wesley AllenChief Financial Officer | Buy | 1,000 1,000 held | $5.10 | 09/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ATON
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ATON for Q2 2026. | ||||
ATON Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATON ranks across every disease it competes in
Competitive Position is a premium feature
See how ATON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATON News
About AlphaTON Capital Corp.
Founded1973
BIOPHARMAWATCH ELITE PLUS
Trade the next ATON catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime